Yissum Ltd.

54 articles about Yissum Ltd.

• Yissum Ltd. Signs a Collaboration Agreement with Aurum Ventures MKI for the Development of Breakthrough Liver-Bypassing Oral Drug Delivery Nanotechnology

  6/15/2009

• Yissum Ltd. Introduces Novel Compound for the Treatment of Osteoporosis

  6/9/2009

• Yissum Ltd. Appoints Yaacov Michlin as Chief Executive Officer

  4/6/2009

• Yissum Ltd. Announces Nanotechnology for Increased Bioavailability of Compounds Wins Prestige Award

  2/4/2009

• Yissum Ltd. Announces Departure of Nava Swersky Sofer, President & CEO, After Three-Year Term

  12/29/2008

• Yissum Ltd. Subsidiary Jexys Pharmaceuticals Announces Strategic R&D Collaboration Agreement with Teva Pharmaceutical Industries Limited

  12/15/2008

• BioLineRx Ltd. and Yissum Ltd. Sign a Licensing Agreement for the Development of a Novel Compound for the Treatment of Inflammatory Bowel Disease

  11/12/2008

• Yissum Ltd. Introduces Novel Device for Improved Saliva Based Medical Diagnostics

  5/27/2008

• Yissum Ltd. Announces the Launch of the Hebrew University of Jerusalem's Genetic Resource for Studies of Common Diseases

  3/11/2008

• Yissum Ltd. Announces the Discovery of a Novel Small Molecule With Potent Anti-Metastatic Activity

  2/27/2008

• Protalix Biotherapeutics Extends Research Agreement With Yissum Ltd. Based on Promising Acetylcholinesterase Program Results in Animal Study

  1/22/2008

• Yissum Ltd. and Eucalyptus Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases

  1/8/2008

• Yissum Ltd. Spins Off Start-Up Nanolymf to Advance Breakthrough Liver-Bypassing Oral Drug Delivery Technology

  12/20/2007

• BioLineRx Ltd. In-Licenses Anti-Cancer Compound BL-4060

  11/15/2007